MCL is a relatively rare subtype of non-Hodgkin’s lymphoma (NHL). Unlike other inert non-Hodgkin’s lymphomas, MCL often leads to poorer clinical outcomes and shorter overall survival. The treatment of lymphoma remains a challenging topic, and there is a lack of widely accepted and approved first-line standard treatment options. Especially in elderly patients over 65 years of age, who are usually not suitable for intensive chemotherapy (e.g., high-dose cytarabine) or autologous stem cell transplantation, there is an urgent need for effective new therapeutic agents. A clinical study for the treatment of patients with newly diagnosed neoplastic lymphoma has been approved by the State Food and Drug Administration and is currently underway at our hospital. The study will confirm the efficacy of a new drug for newly diagnosed lymphoma. If you or a friend or relative has been newly diagnosed with a new diagnosis of lymphoma, you may be considered for the study. Once you meet the enrollment criteria and join the program, the drug and study-related tests will be provided free of charge. Important entry criteria: 1. Patients newly diagnosed with MCL who are in good physical condition (physical fitness score: 0-1) 2. History of stroke or intracranial hemorrhage, central nervous system lymphoma, uncontrolled active systemic infection, major cardiovascular disease and other malignancies within 6 months.